All News | FDA

Advertising & Promotion

Oct 2, 2019
District Court Dismisses Whistleblower Case Over AbbVie Ambassador Program
Oct 2, 2019
J&J Settles in Opioid Marketing Bellwether Case
Sep 30, 2019
Avanir Settles Claims Involving Nuedexta Marketing
Sep 30, 2019
OPDP Issues Two Enforcement Letters in September Citing Risk Information
Sep 16, 2019
Court Allows RICO Claims To Continue in Multidistrict Opioid Litigation
Sep 14, 2019
More Hospitals Sue Opioid Makers
Sep 13, 2019
Pennsylvania Files Lawsuit Against Sackler Family
Sep 12, 2019
Mallinckrodt To Pay $15.4 Million To Settle Allegations of Paying Physicians To Prescribe Acthar
Sep 11, 2019
FTC Sends Warning Letters to Three Companies Over CBD Product Claims
Sep 11, 2019
U.S. Chamber, 13 States, and D.C. File Amicus Briefs Supporting Halt or Delay of Opioid ‘Bellwether’ Trials

Good Clinical Practice

Oct 11, 2019
Genetic Testing Company Resolves FCA Case Over Clinical Trial Scheme
Oct 11, 2019
FDA Will Have Workshop Nov. 12 on Pediatric Engagement to Develop Trial Endpoints
Oct 11, 2019
FDA Issues Final Guidance on Streamlined Process for Oncology Trial IVDs
Oct 10, 2019
JAMA Viewpoint Contends U.S. Oversight System May Not Be Able To Deal With Pay-to-Participate Trials
Oct 9, 2019
FDA Guidance Discusses Trial Designs for ALS Drugs
Oct 9, 2019
ClinicalTrials.gov Adds Four Frequently Asked Questions
Oct 8, 2019
Transitioning to New Technologies Difficult for Trial Sites
Oct 7, 2019
Kentucky Appeals Court Remands Consent Case
Oct 7, 2019
Court Cases May Change EMA’s Transparency Policies
Oct 5, 2019
Collins, Two Others Plead Guilty to Insider Trading Over Trial Disclosure

U.S. Food Labeling

Sep 25,2017
USDA Releases Report on Using QR Codes for Foods with GMOs
Sep 20,2017
CFSAN Schedules Meeting on Pre-DSHEA Supplements
Sep 18,2017
CFSAN Shuffles ‘Competing Priorities’
Sep 18,2017
Parties Settle in Health Supplement Promotion Case
Sep 18,2017
CFSAN Wants Ideas on Reducing Regulatory Burdens
Sep 18,2017
FDA Allows First Qualified Health Claim To Prevent Food Allergy
Sep 12,2017
FDA Promises Further Menu Labeling Guidance by Year End
Sep 5,2017
Plaintiffs Are Awarded $8.25 Million in Class Action Suit
Sep 5,2017
CFSAN Schedules Meeting on Pre-DSHEA Ingredients
Aug 29,2017
FSIS Revises Label Approval Guideline

FDA Regulation & Enforcement

Medical Devices

Copyright © Thompson FDA, a division of CBIS. All rights reserved.